3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
123
Melanoma
92
Neoplasms
82
Colorectal Neoplasms
62
Squamous Cell Carcinoma of Head and Neck
61
Neoplasm Metastasis
58
Triple Negative Breast Neoplasms
49
Carcinoma, Renal Cell
47
Breast Neoplasms
38
Lung Neoplasms
36
Ovarian Neoplasms
32
Pancreatic Neoplasms
30
Head and Neck Neoplasms
29
Stomach Neoplasms
28
Urinary Bladder Neoplasms
26
Carcinoma, Transitional Cell
26
Parkinson Disease 4, Autosomal Dominant Lewy Body
23
Endometrial Neoplasms
23
Uterine Cervical Neoplasms
21
Carcinoma, Hepatocellular
18
Recurrence
15
Esophageal Neoplasms
15
Prostatic Neoplasms
14
Lymphoma
14
Carcinoma, Squamous Cell
12
Small Cell Lung Carcinoma
11
Kidney Neoplasms
11
Cholangiocarcinoma
11
Advanced Solid Tumor
11
Solid Tumor
10
Interventions
Doxorubicin
4
ribociclib
2
belinostat
2
Radiotherapy
2
siremadlin
1
selinexor
1
sargramostim
1
romidepsin
1
peposertib
1
pembrolizumab
1
liposomal doxorubicin
1
ixazomib
1
eribulin
1
cixutumumab
1
avelumab
1
Trabectedin
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Magnetic Resonance Spectroscopy
1
Ifosfamide
1
Histamine H2 Antagonists
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Famotidine
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Celecoxib
1
Biopsy
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Liposarcoma
×
pembrolizumab
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled